National Bank of Canada FI Trims Stock Holdings in Haleon plc (NYSE:HLN)

National Bank of Canada FI decreased its holdings in shares of Haleon plc (NYSE:HLN) by 43.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,730 shares of the company’s stock after selling 3,649 shares during the quarter. National Bank of Canada FI’s holdings in Haleon were worth $50,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Fortitude Family Office LLC bought a new stake in shares of Haleon during the 3rd quarter valued at $28,000. Cultivar Capital Inc. purchased a new position in Haleon during the 2nd quarter valued at about $40,000. Prospera Private Wealth LLC bought a new stake in shares of Haleon during the third quarter valued at about $57,000. BOKF NA lifted its holdings in shares of Haleon by 68.8% in the second quarter. BOKF NA now owns 6,972 shares of the company’s stock worth $58,000 after buying an additional 2,842 shares in the last quarter. Finally, Rothschild Investment LLC purchased a new stake in shares of Haleon in the second quarter worth about $60,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 2.1 %

HLN stock opened at $9.93 on Wednesday. The company’s 50 day moving average is $9.74 and its 200 day moving average is $9.54. The stock has a market cap of $44.93 billion, a price-to-earnings ratio of 29.15, a price-to-earnings-growth ratio of 2.95 and a beta of 0.28. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80.

Analysts Set New Price Targets

HLN has been the subject of several recent analyst reports. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley upped their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.